Trials / Completed
CompletedNCT00106613
A Research Study for Patients With Metastatic Renal Cell Carcinoma
An Exploratory Phase II, Multicenter, Open-label Trial Evaluating the Activity and Tolerability of FK228 in Patients With Metastatic Renal Cell Carcinoma That is Progressive Following or During Immunotherapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the activity of FK228 in metastatic renal cell carcinoma (RCC) patients who have developed progressive disease (PD) following or during treatment with immunotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FK228 (romidepsin) | Patients receive 13 mg/m2 of romidepsin (FK228) intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle. |
Timeline
- Start date
- 2003-05-01
- Primary completion
- 2004-08-01
- Completion
- 2004-08-01
- First posted
- 2005-03-29
- Last updated
- 2019-10-18
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00106613. Inclusion in this directory is not an endorsement.